Literature DB >> 17024664

Genotype-phenotype correlations in von Hippel-Lindau disease.

Kai Ren Ong1, Emma R Woodward, Pip Killick, Caron Lim, Fiona Macdonald, Eamonn R Maher.   

Abstract

von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome resulting from mutations in the VHL tumor suppressor gene. VHL disease displays marked variation in expression and the presence of pheochromocytoma has been linked to missense VHL mutations. We analyzed genotype-phenotype correlations in 573 individuals with VHL disease. Routine clinical and radiological surveillance of VHL patients and at-risk relatives was associated with increased detection of retinal angiomatosis (73 vs. 59% of cases) and a reduction in age at diagnosis of renal cell carcinoma (RCC) (44.0+/-10.9 vs. 39.7+/-10.3 years). We confirmed the association of pheochromocytoma with missense mutations described previously, but stratifying missense mutations into those that resulted in substitution of a surface amino acid and those that disrupted structural integrity demonstrated that surface amino acid substitutions conferred a higher pheochromocytoma risk. Age at first manifestation of VHL disease was significantly earlier (P=0.001), and age-related risks of retinal angiomas and RCC were higher (P=0.022 and P=0.0008, respectively) in individuals with a nonsense or frameshift mutation than in those with deletions or missense mutations that disrupted the structural integrity of the VHL gene product (pVHL). These results extend genotype-phenotype-protein structure correlations in VHL disease and provide a baseline for future chemoprevention studies in VHL disease. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17024664     DOI: 10.1002/humu.20385

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  73 in total

1.  Clinical utility gene card for: von Hippel-Lindau (VHL).

Authors:  Jochen Decker; Christine Neuhaus; Fiona Macdonald; Hiltrud Brauch; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

Review 2.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

Review 3.  Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?

Authors:  Lauren Fishbein
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

4.  Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Authors:  Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman
Journal:  Eur Urol       Date:  2019-07-18       Impact factor: 20.096

Review 5.  Edgotype: a fundamental link between genotype and phenotype.

Authors:  Nidhi Sahni; Song Yi; Quan Zhong; Noor Jailkhani; Benoit Charloteaux; Michael E Cusick; Marc Vidal
Journal:  Curr Opin Genet Dev       Date:  2013-11-26       Impact factor: 5.578

Review 6.  Update on pediatric pheochromocytoma.

Authors:  Bas Havekes; Johannes A Romijn; Graeme Eisenhofer; Karen Adams; Karel Pacak
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

7.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

8.  VHL frameshift mutation as target of nonsense-mediated mRNA decay in Drosophila melanogaster and human HEK293 cell line.

Authors:  Lucia Micale; Lucia Anna Muscarella; Marco Marzulli; Bartolomeo Augello; Patrizia Tritto; Leonardo D'Agruma; Leopoldo Zelante; Gioacchino Palumbo; Giuseppe Merla
Journal:  J Biomed Biotechnol       Date:  2010-01-21

9.  Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.

Authors:  A D Sorrell; S Lee; C Stolle; J Ellenhorn; A Grix; W G Kaelin; J N Weitzel
Journal:  Clin Genet       Date:  2011-06       Impact factor: 4.438

10.  Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.

Authors:  Christopher Ricketts; Maurice P Zeegers; Jan Lubinski; Eamonn R Maher
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.